Mirae Asset Global Investments Co. Ltd. Sells 132,411 Shares of DexCom, Inc. (NASDAQ:DXCM)

Mirae Asset Global Investments Co. Ltd. lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 50.4% in the 3rd quarter, Holdings Channel reports. The firm owned 130,261 shares of the medical device company’s stock after selling 132,411 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in DexCom were worth $8,765,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in DXCM. Canada Pension Plan Investment Board boosted its position in shares of DexCom by 189.1% in the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after acquiring an additional 435,401 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in DexCom by 16.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares during the period. Assenagon Asset Management S.A. boosted its holdings in DexCom by 53.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after purchasing an additional 345,114 shares during the period. Bellevue Group AG grew its position in shares of DexCom by 33.5% during the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock valued at $169,380,000 after purchasing an additional 306,604 shares in the last quarter. Finally, Magnetar Financial LLC bought a new position in shares of DexCom in the second quarter worth $31,793,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other DexCom news, EVP Sadie Stern sold 426 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,824 shares of company stock worth $126,390. 0.30% of the stock is currently owned by company insiders.

DexCom Price Performance

Shares of DexCom stock opened at $73.44 on Monday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The business’s 50 day simple moving average is $70.11 and its two-hundred day simple moving average is $97.95. The stock has a market capitalization of $29.21 billion, a P/E ratio of 47.38, a price-to-earnings-growth ratio of 2.26 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.34 EPS. Analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DXCM shares. Barclays reduced their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. UBS Group cut their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday. Finally, StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a report on Friday. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.